Mainz Biomed secured UK Medicines and Healthcare Products Regulatory Agency approval for ColoAlert, a PCR-based stool DNA biomarker test for colorectal cancer detection. Following its Swiss registration, this clearance supports broader European commercialization. Mainz Biomed also partnered with UK’s EDX Medical Group to advance early cancer detection, including development of next-generation tests combining mRNA markers and immunohistochemistry.